91 results about "Vaginal epithelial cell" patented technology

Disclosed is a cervico-vaginal tissue equivalent comprised of vaginal epithelial cells and immune cells, cultured at the air-liquid interface. The tissue equivalent is capable of being infected with a sexually transmitted pathogen such as a virus (e.g., HIV), a bacteria, a helminthic parasite, or a fungus. The tissue equivalent is also capable of undergoing an allergic-type reaction or an irritant-type reaction. The tissue equivalent is characterized as having nucleated basal layer cells and nucleated suprabasal layer cells, and further as having cell layers external to the suprabasal layer progressively increasing in glycogen content and progressively decreasing in nuclei content. Immune cells of the tissue equivalent are primarily located in the basal and suprabasal layers. Also disclosed are methods for producing the tissue equivalent. The methods involve providing vaginal epithelial cells and immune cells, seeding the cells onto a porous support, and co culturing the seeded cells at the air-liquid interface under conditions appropriate for differentiation. One such method disclosed is for generation of the tissue equivalent in serum free medium. Specific cells from which the tissue equivalent is generated, and also specific preferred components of the medium in which the tissue equivalent is generated are provided. Also disclosed is a cervico-vaginal tissue equivalent produced by the methods disclosed herein.

The invention discloses a Lactobacillus crispatus 262-1 and its application in gynecological diseases. The Lactobacillus crispatus 262-1 is a new Lactobacillus crispatus strain, and has a preservation number of CGMCCNo.6469 in China General Microbiological Culture Collection Center. The Lactobacillus crispatus 262-1 has the advantages of strong acid and H2O2 production ability, strong adherence to vaginal epithelial cells, substantial resistance on bacterial vaginal diseases and various vaginal gynecological diseases, safety, non-toxicity, good stability and long term preservation. The invention also relates to a use of the Lactobacillus crispatus 262-1 in medicines for preventing and/or treating the gynecological diseases.

The invention belongs to the field of probiotics and relates to Lactobacillus crispatus SQ1505. The Lactobacillus crispatus SQ1505 has great performances of acid and hydrogen peroxide production and biofilm formation, has an adhesion effect on human vaginal epithelial cells and an antibacterial effect on vaginal pathogenic bacteria, can be used for prevention and treatment of vaginitis and is a new-generation probiotic capable of replacing antibiotics for preventing and treating female reproductive tract infections.

The present invention discloses one plant lactobacillus strain and its application. The plant lactobacillus, Lactobacillus plantarum L323 CGMCC No. 1329, is separated from Chinese pregnant woman's vaginal secretion, and has relatively high bacteriotasis on common vaginal pathogens, such as staphylococcus aureus, candida albicans, colibacillus and vaginal Gardnar bacillus, and acid producing and H2O2 producing capacity higher than other lactobacillus. The plant lactobacillus, Lactobacillus plantarum L323 CGMCC No. 1329, may be used in preparing vaginal microbial preparation for preventing and/or treating vaginal infectious diseases.

The invention provides lactobacillus gasseri and application thereof for preparing vaginal bacteriostatic drugs. The lactobacillus gasseri is collected in China General Microbiological Culture Collection Center, and has a collection number of CGMCC No. 14109. Study of metabolic performance of the lactobacillus gasseri discovers that, compared with ordinary lactobacillus gasseri, the strain has high lactic acid and hydrogen peroxide production capacity, is excellent in bacteriostatic ability of pathogenic bacteria, and also has outstanding vaginal epithelial cell adhesion ability. Based on theprevious discovered novel properties, the invention further provides application of the lactobacillus gasseri in preparation of vaginal bacteriostatic drugs, so that treatment of multiple bacterial vaginal diseases can be realized. The bacterium agent disclosed by the invention has obvious effects on the bacterial vaginal diseases and is safe, non-toxic, excellent in stability and capable of beingpreserved for a long time. The invention further relates to application of the lactobacillus gasseri in medicines for preventing and/or treating gynecological diseases.

The present invention provides a strain, which is a Lactobacillus crispatus strain and is characterized in that the preservation number is CGMCC No.6360. The present invention further provides uses of the strain in preparation of drugs for prevention and/or treatment of vaginitis, preparation of vagina care products, and preparation of external genitalia sanitary products. With the technical scheme, antagonism effects of the Lactobacillus crispatus strain on multiple pathogenic bacteria can be achieved. In addition, the strain has high adhesion to vaginal epithelial cells. The strain can well meet practical clinical application requirements.

The invention discloses lactobacillus for producing lactic acid and H2O2 and an application of the lactobacillus. The lactobacillus is lactobacillus gasseri or lactobacillus crispatus, wherein the preservation number of the lactobacillus gasseri is CGMCC No. 15815 or CGMCC No. 15816; the preservation number of the lactobacillus crispatus is CGMCC No. 15813 or CGMCC No. 15814. The lactobacillus gasseri and lactobacillus crispatus provided by the invention have extremely strong lactic acid and H2O2 production ability, have good ability to adhere to vaginal epithelial cells, and can effectively inhibit reproduction of pathogenic bacteria like Gardner bacteria and Candida albicans in in-vivo and in-vitro experiments.

The invention discloses lactobacillus jensenii and application thereof. The lactobacillus jensenii is particularly lactobacillus jensenii IMJ-1, and the file No. of the lactobacillus jensenii IMJ-1 in the General Microbiological Culture Collection Center of China Microbial Culture Collection Management Committee is CGMCC No. 6558. The lactobacillus jensenii IMJ-1 CGMCC No.6558 has high H2O2 generation capability, can effectively suppress breeding of external pathogenic bacteria and other conditional pathogenic bacteria, and has a high binding function to epithelial cells of vagina, and accordingly, breeding of bacteria strains on the vaginal epithelium is guranteed. Besides, the lactobacillus jensenii IMJ-1 CGMCC No. 6558 has a certain application prospect in preventing and curing bacterial vaginosis.

The invention provides lactobacillus rhamnosus and application thereof to preparation of a vaginal antibacterial medicine. The lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.14184. According to research on the metabolic performance of the lactobacillus rhamnosus, compared with the common lactobacillusrhamnosus, the lactobacillus rhamnosus has higher production capacity of lactic acid and hydrogen peroxide, has higher antibacterial capability on pathogenic bacteria and has prominent vagina epithelial cell adhesion capacity. Based on the above discovered new performance, the new application of the lactobacillus rhamnosus to preparation of the vaginal antibacterial medicine is determined, and various bacterial vaginal diseases can be treated. The lactobacillus rhamnosus has remarkable effect on the bacterial vaginal diseases, is safe, non-toxic and high in stability and can be stored for a long time. The invention also relates to application of the lactobacillus rhamnosus to medicines for preventing and/or treating gynecological diseases.

The invention provides a strain. The strain is a Lactobacillus crispatus strain, and the preservation number of the strain is CGMCC No.6364. The invention also provides a use of the strain in the preparation of colpitis prevention and/or treatment drugs, a use of the strain in the preparation of vagina nursing articles, and a use of the strain in the preparation of external genitals health articles. By adopting the above technical scheme, the strain can effectively realize an antagonistic effect on a plurality of pathogenic bacteria. The strain has a high adherence ability to vaginal epithelial cell. The strain can well meet practical clinic application demands.

The invention provides lactobacillus reuteri and an application of the lactobacillus reuteri in preparing a vaginal antibacterial drug. The lactobacillus reuteri is collected in China General Microbiological Culture Collection Center with a collection number of CGMCC No. (China General Microbiological Culture Collection Center number) 14110. A study of metabolic performance of the lactobacillus reuteri finds that the strain has better lactic acid production capacity, very strong hydrogen peroxide generation capacity, very strong antibacterial capacity on pathogenic bacteria and excellent vaginal epithelial cell adhesive capacity compared with the common lactobacillus reuteri. Based on the above novel properties found, the novel application of the lactobacillus reuteri in preparing the vaginal antibacterial drug is determined, and treatment of multiple bacterial vaginal diseases can be achieved. The lactobacillus reuteri has a significant effect on the bacterial vaginal diseases, is safe, nontoxic and good in stability and can be stored for a long term. The invention further relates to an application of the lactobacillus reuteri in drugs for preventing and/or treating gynecological diseases.

The invention relates to a method for preventing or treating urogenital infections in females, which comprises administering a pharmaceutical preparation comprising, in combination with a suitable galenical carrier, a therapeutically effective amount of at least one lactic acid bacteria strain of the genus L. acidophilus, L. crispatus, L. gasseri, L. helveticus and L. jensenii selected for their ability to kill urogenital and/or gastrointestinal pathogens and their ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within vaginal epithelial cells, as well as for their ability to modulate a humoral and/or cellular immune response at the vaginal and/or gastrointestinal level, in particular to inhibit the inflammatory syndrome as well as the infectious syndrome.

The present invention discloses Lactobacillus crispatus 262-1 and an inoculum comprising such strain and application thereof. The Lactobacillus crispatus 262-1 is a new strain of Lactobacillus genus and is preserved in the China General Microbiological Culture Collection Center with a preservation number of CGMCC No. 6469. The Lactobacillus crispatus 262-1 particularly is the dominant bacteria in the vagina, has good acid and H₂O₂ production capability, good adhesion to the vaginal epithelial cells and significant resistance to bacterial vaginosis and various vaginal infections, and is characterized by safety, non-toxicity, good stability and long term preservation. The present invention also relates to the use of the Lactobacillus crispatus 262-1 in the preparation of pharmaceuticals for preventing and/or treating gynecological diseases and its application in feminine care products such as medical instruments, disinfect products or cosmetics.

The invention discloses lactobacillus crispatus and application thereof. The perseveration number of the lactobacillus crispatus is as follows: CGMCC No.9388. The lactobacillus crispatus IMC-12 disclosed by the invention has relatively strong capacity of producing H2O2 and can be used for effectively inhibiting the growth of external pathogenic bacteria and other conditioned pathogenic bacteria and meanwhile, the lactobacillus cripatus has relatively strong adhesive attraction for vagina epithelial cells, so that the field planting of the vagina epithelial cell is guaranteed, and thus, the lactobacillus crispatus IMC-12 has certain application prospect in preventing and treating urogenital tract infection.

The invention discloses lactobacillus curvatus and pharmaceutical application thereof. The lactobacillus curvatus provided by the invention specifically is lactobacillus curvatus IMC-79 which has a relatively strong capability of generating H2O2 and can effectively inhibit the growth of external pathogenic bacteria and other conditioned pathogens; and meanwhile, the lactobacillus curvatus IMC-79 also has a relatively strong effect of adhering vaginal epithelial cells to ensure that a strain is fixedly planted on the vaginal epithelium. The lactobacillus curvatus IMC-79 provided by the invention has a certain application prospect in the aspect of preventing and treating bacterial vaginal diseases.

The invention provides a strain. The strain is a Lactobacillus crispatus strain, and the preservation number of the strain is CGMCC No.6363. The invention also provides a use of the strain in the preparation of colpitis prevention and/or treatment drugs, a use of the strain in the preparation of vagina nursing articles, and a use of the strain in the preparation of external genitals health articles. By adopting the above technical scheme, the strain can effectively realize an antagonistic effect on a plurality of pathogenic bacteria. The strain has a high adherence ability to vaginal epithelial cell. The strain can well meet practical clinic application demands.

The invention relates to the field of traditional Chinese medicines, in particular to a medicine composition for treating vaginitis, which comprises the following components in percentage by weight: 0.1-20.0 percent of blue lotus essential oil, 0.1-20.0 percent of borneol essence, 0.5-5.0 percent of vitamin E, 0.5-15.0 percent of arginine and 0.5-1.0 percent of nitroglycerin or pentaerythritol tetranitrate. The invention also provides a gel of the medicine composition and a preparation method thereof. The medicine composition and the gel thereof can improve the blood circulation around vagina and prevent premature aging of epithelial cells of the vagina, and have no side effect and potential risk on human bodies after long-time use. In the invention, antibiosis experiments show that the medicine composition can inhibit the growth of various pathogenic bacteria, acute skin irritancy tests show that no toxic reaction is found, the microbiological indices of the medicine composition reach the standard, and no pathogenic bacteria exists, thereby the invention has a wide application prospect.

The invention discloses a lactobacillus jensenii and application thereof. The lactobacillus jensenii disclosed by the invention is named as IMJ-19, and is collected in the China General Microbiological Culture Collection Center on July 14th, 2014, with the collection number of CGMCC No.9439. The lactobacillus jensenii IMJ-19 has strong capability of generating H2O2, can effectively inhibit the growth of foreign pathogenic bacteria and other conditioned pathogens, also has strong adhesion action to vagina epithelial cells, and ensures the colonization of strains on vaginal epithelial, and the lactobacillus jensenii IMJ-19 has certain application prospects on the aspect of prevention and treatment of urogenital tract infection.

The invention provides lactobacillus jensenii and application thereof for preparing vaginal bacteriostatic drugs. The lactobacillus jensenii is deposited in the China General Microorganisms CollectionCenter of China Committee for Culture Collection of Microorganisms, and the preservation number is CGMCC No. 14112. Research on the metabolic performance of the lactobacillus jensenii provided by theinvention discovers that, compared to ordinary lactobacillus jensenii, the strain has high lactic acid production capacity, high hydrogen peroxide production capacity, high bacteriostatic ability topathogenic bacteria, and outstanding vaginal epithelial cell adhesion ability. Based on the new properties discovered above, the invention determines a new use of the lactobacillus jensenii for preparing the vaginal bacteriostatic drugs, and the vaginal bacteriostatic drugs can realize treatment of a variety of bacterial vaginal diseases. The bactericidal agent provided by the invention has obvious effects on bacterial vaginal diseases, is safe and non-toxic, has good stability, and can be stored for a long time. The invention also relates to the use of the lactobacillus jensenii in drugs forprevention and/or treatment of gynecological diseases.

The suppository for treating mycotic vaginitis contains tinidazole, fungicidin and chlorhexidine in certain proportion, and is prepared through mixing tinidazole, fungicidin and chlorhexidine in certain proportion in some container and filling into administration unit with each suppository weighing 0.5 g. The suppository is administrated via vagina and absorbed through mucous membrane to kill fungi in vagina. It may also promote the proliferation of epidermis cell in vagina, regulate pH value in vagina, raise antifungus capacity, improve the permeability of cell membrane and reduce exudation and has no negative effect.